24 05, 2017

Gilead forced to withdraw Truvada® patent application in Argentina

2020-08-04T17:14:34-03:00miércoles, 24 mayo, 2017|Producciones en inglés|

The decision, for which the Fundación GEP contributed with/to decisive arguments, paves the way to generic versions to facilitate access to treatments. Por: Julia Varela May 23, 2017 - In a resolution that means a step forward in safeguarding the right to health, Argentina’s patent office (the National Institute of Industrial Property - INPI) forced

14 02, 2017

GEP filed new opposition to patent request for Hepatitis C drug in Argentina

2020-08-04T17:19:32-03:00martes, 14 febrero, 2017|Producciones en inglés|

Por: Julia Varela BUENOS AIRES, February 14, 2017 - The GEP Foundation and Intiative for Medicines, Access and Knowledge (IMAK) filed yesterday an opposition at the National Institute of Industrial Property (INPI) to the patent request by multinational pharmaceutical company Gilead on the base compound of sofosbuvir, a drug that represents the cure for hepatitis C. The action means a great step to

15 09, 2016

Big Pharma’s court cases in Brazil & Argentina threaten national laws considered important public health safeguards in the UN HLP report

2020-08-04T17:29:58-03:00jueves, 15 septiembre, 2016|Producciones en inglés|

September 15th 2016 - Press release Fundación Grupo Efecto Positivo (FGEP) - Associação Brasileira Interdisciplinar de AIDS (ABIA) - Grupo de Trabalho sobre Propriedade Intelectual (GTPI) United Nations’ High Level Panel on Access to Medicines Report released: Big Pharma’s court cases in Brazil & Argentina threaten to dismantle the national laws considered as important public health safeguards

5 02, 2016

FGEP and other Latin American organizations requested a Thematic Hearing at the Inter-American Commission on Human Rights

2018-02-05T10:36:13-03:00viernes, 5 febrero, 2016|Advocacy, Direct Action, Hepatitis C, HIV, Medicines, Public Health, RedLAM|

Por: Julia Varela   GEP Foundation (FGEP), along with more than 20 other civil society organizations from different countries in Latin America committed to defending the right to health, requested last January 18th a Thematic Hearing at the Inter-American Commission on Human Rights (IACHR) on the issue of lack of access to medicines. The request

17 12, 2015

FGEP continues defense of public health in Argentina against the abuse of the patent system by multinational pharmaceutical companies

2015-12-17T03:50:58-03:00jueves, 17 diciembre, 2015|Access to Medicines, Argentina, Direct Action, Health Safeguards, HIV, Intellectual Property, Kaletra, Patent opposition, Sofosbuvir|

BUENOS AIRES, December 15th 2015 - Fundación Grupo Efecto Positivo (FGEP), an organization whose work is focused on guaranteeing access to essential medicines for HIV and Hepatitis C in Argentina and Latin America, announced in a press conference on November 30th two new key actions to defend public health policies. Dr. Daniel Gollán, Argentina’s Minister

10 11, 2015

Regulatory Agency in Argentina approved sofosbuvir and a local pharmaceutical company announced the entry into the market of its generic version

2015-11-14T16:07:28-03:00martes, 10 noviembre, 2015|Hepatitis C, Medicines, Patent opposition, Sofosbuvir|

Buenos Aires, November 10, 2015 - Argentine Medicines Regulatory Agency, ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) approved last week commercialization of a relevant medicine to treat Hepatitis C. “This measure was highly expected since it is the first step to ensure availability of this essential medicine in our country. I live with Hepatitis

4 11, 2015

Argentina could save U$11M per year buying generic version of Truvada®

2015-11-04T20:01:06-03:00miércoles, 4 noviembre, 2015|Access to Medicines, Advocacy, Health Safeguards, Intellectual Property, Patent opposition|

The Argentine Community of People Living with HIV requested the rejection of a patent for an essential HIV/AIDS medicine. If the Argentine Patent Office does grant the this request, Argentina could produce generic versions at a lower cost representing a potential saving of over US$11 million. Argentina April 13th, 2015.- The Grupo Efecto Positivo Foundation (FGEP) in collaboration with the Argentine

11 09, 2015

UNAIDS “4th 90”: Affordability of Medicines

2015-11-04T16:38:17-03:00viernes, 11 septiembre, 2015|909090 Strategy, Access to Medicines, Argentina, Medicines, Ministry of Health, Public Health, UNAIDS|

UNAIDS has seen Argentina´s proposal to add a 4th “90” to its 909090 Strategy as a model to be implemented worldwide Buenos aires, September 2015 – UNAIDS´s Executive Director, Michel Sidibé, visit Argentina and Chile in his first time visit to Latin American region as part of a global tour to promote 90-90-90 strategy which

27 08, 2015

People living with HepC denounced high prices of the pharmaceutical industry

2015-11-04T20:18:54-03:00jueves, 27 agosto, 2015|Direct Action, Hepatitis C, Intellectual Property, Patent opposition, Public Health|

Buenos Aires, August 27th 2015 - Members of Grupo Efecto Positivo Foundation (FGEP) accompanied by other civil society organizations and representatives held a direct action during the 2015 Hepatitis International Symposium organized by Fundación Huesped. The action aimed to denounce monopolies and high prices of drugs to treat hepatitis C and took place during the presentation of Dr.

Ir a Arriba